Year: 2024
Type: article
Abstract: The concept of pre-diabetes has led to provision of measures to reduce disease progression through identification of subjects at risk of diabetes. We previously considered the idea of pre-asthma in relation to allergic asthma and considered that, in addition to the need to improve population health via multiple measures, including reduction of exposure to allergens and pollutants and avoidance of obesity, there are several possible specific means to reduce asthma development in those most at risk (pre- asthma). The most obvious is allergen immunotherapy (AIT), which when given for allergic rhinitis (AR) has reasonable evidence to support asthma prevention in children (2) but also needs further study as primary prevention. In this second paper we explore the possibilities for similar actions in late onset eosinophilic asthma.
DOI: 10.17615/an9d-5n42
Authors: Hopkins, C., Jesenak, M., Kappen, J., Senior, B., Johansen, P., Mullol, J., Scadding, G. K., Reitsma, S., Price, D., De Corso, E., Scadding, G., Toppila-Salmi, S., McDonald, M., Gray, C., Thyssen, J. P., Backer, V., Quirce, S., Diamant, Z., Bernal-Sprekelsen, M., Hellings, P. W., Wahn, U., Conti, D. M.
Institution: University of North Carolina at Chapel Hill
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Teva Pharmaceutical Industries, CSL Behring, Stryker, Regeneron Pharmaceuticals, American Rhinologic Society, Allergy Therapeutics, Amsterdam University Medical Centers, Glenmark Pharmaceuticals, Coloplast, Swedish Orphan Biovitrum, AKL Research and Development, LEO Pharma, Genentech, Sanofi Genzyme, Sanofi Pasteur, Efficacy and Mechanism Evaluation Programme, UCB Pharma
OpenAlex ID: W4404670223